Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation

Lancet. 1995 Nov 25;346(8987):1399-400. doi: 10.1016/s0140-6736(95)92408-6.


Mutations in codon 12 of K-RAS are frequently found in pancreatic adenocarcinomas. T-cell responses specific for individual RAS mutations can be elicited in vitro by stimulation of peripheral blood mononuclear cells with synthetic peptides. Mutant ras peptides are therefore a candidate vaccine for specific immunotherapy in pancreatic carcinoma patients. When vaccinated with a synthetic ras peptide representing the K-RAS mutation in their tumours, a transient ras-specific T-cell response was induced in two of five patients treated. The vaccination protocol involved multiple infusions of large amounts of peptide-pulsed antigen-presenting-cells obtained by leucapheresis. These results indicate that specific T-cell responses against mutations uniquely harboured in tumour cells can be induced in cancer patients by vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / genetics
  • Adenocarcinoma / therapy*
  • Antigen-Presenting Cells / immunology
  • Humans
  • Immunotherapy / methods*
  • Leukapheresis
  • Mutation
  • Pancreatic Neoplasms / genetics
  • Pancreatic Neoplasms / therapy*
  • T-Lymphocytes / immunology*
  • ras Proteins / genetics
  • ras Proteins / immunology*


  • ras Proteins